Nov 27 (Reuters) - The U.S. Food and Drug Administration (FDA) on Monday approved SpringWorks Therapeutics' drug for treating a type of non-cancerous soft-tissue tumor in adults. (Reporting by Pratik Jain in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.44 USD | -2.73% | -2.21% | +13.55% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
41.44 USD | -2.73% | -2.21% | 3.07B | ||
28.66 USD | +1.63% | -0.76% | 162B | ||
28.24 EUR | +0.66% | +2.21% | 30.09B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.55% | 3.07B | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- SWTX Stock
- News SpringWorks Therapeutics, Inc.
- US FDA approves SpringWorks Therapeutics' non-cancerous tumor treatment